C1S
Complement C1s subcomponent
As of the edition of 20 October 2026, C1S (complement C1s subcomponent, UniProt P09871) has 3 drugs tested at it and 4 companies on the list, 0 on route A and 2 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P09871
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 14
- Disease areas
- Immune system; Heart and blood vessels; Skin and connective tissue; Inherited and neonatal; Blood and lymph; Nervous system; Lungs and airways; Pregnancy and women's health
- Registered trials of its drugs
- 33
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 2 |
| Active | 1 |
| Total | 3 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Human c1-esterase inhibitor | Marketed | Phase 4 | Ended 2025 |
| Riliprubart | Active | Phase 3 | none listed |
| Sutimlimab | Marketed | Phase 3 | Ends 2034 |
3 of 3 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route B | 2 |
| Engaged | 1 |
| Undetermined | 1 |
| Total on the list | 4 |
| Company | Route |
|---|---|
| Sanofi | Route B |
| Recordati Rare Diseases | Route B |
The other 2 companies at C1S
In the product4 companies in all; 2 are not named here, and no score is.
See the 4 companies at C1S, ranked, with the facts behind eachRequest access. Nothing is shown until you do.